This technique, performed in a single center, appears to be feasible and safe. It offers the advantages of laparoscopy and those of endovascular surgery, especially in the challenging conditions encountered during aortic laparoscopic surgery. This approach using existing materials could make laparoscopic aortic surgery for occlusive disease accessible for more vascular surgeons accustomed with laparoscopic surgery.
INTRODUCTION
International recommendations for the treatment of occlusive disease were established by the Trans-Atlantic Inter-Society Consensus II Working Group (TASC II) in
2007.
1 For bilateral and extensive aortoiliac lesions (TASC D), surgical reconstruction is advised. The classic procedure for aortobifemoral bypass is open surgery, which is associated with an overall mortality rate of 3.3%. 2 In 1997, Yves-Marie Dion performed the first totally laparoscopic aortobifemoral bypass using a transperitoneal approach. 3 Since then, it has been considered to be a minimally invasive alternative for treating aortoiliac occlusive disease. 4À7 The authors of the present study, and others, have described the use of a totally retroperitoneal laparoscopic approach as an alternative treatment in cases of hostile abdomen. 8À10 Whatever the approach, the aortoprosthetic anastomosis is a challenging technique, making it unpopular despite obvious advantages for patients. 11 This study presents experience of totally retroperitoneal laparoscopic aortobifemoral bypass performed on 12 patients using a clampless and sutureless technique for the proximal anastomosis. The feasibility and safety of the technique, called EndoVascular REtroperitoneoScopic Technique (EVREST), is evaluated.
MATERIALS AND METHODS

Materials
From February 2012 to March 2013, EVREST was used in 12 patients who presented with TASC D aortoiliac occlusive lesions for which endovascular revascularization was not indicated. Ethical approval was obtained, and all patients gave their informed consent before the procedure. Preoperative evaluation included cardiac stress test, pulmonary function test, and supra-aortic trunk arterial Doppler imaging. Computed tomographic angiography was performed on each patient to confirm TASC D lesions, measure the infrarenal abdominal aortic diameter, and evaluate aortoiliac calcification. The calcification was heavy in five patients (42%), moderate in six (50%), and smooth in one (8%). Inclusion criteria, based on the clinical complaint, clinical findings, and angio CT scan issues, were Fontaine classification from stage II b (claudication <100 m) to IV (tissue loss), and aorto-iliac TASC D lesions with at least 4 cm of patent aorta beneath the renal arteries. Patients with a heavily calcified aorta and patency of the inferior mesenteric artery were not excluded. Exclusion criteria were juxtarenal thrombosis or thrombosed unilateral or bilateral external iliac artery with patent aorta and internal iliac arteries. Patients with TASC D lesions who were not candidates for endovascular treatment were scheduled for EVREST. During the same period, 26 patients underwent an endovascular procedure to treat aortoiliac occlusive disease. Median patient age was 58.2 years (range 45e67 years), with ten males and two females. Median body mass index (BMI) was 25.9 kg/m 2 (range: 21.3e33.5). The EVREST procedure was contraindicated in patients for whom an endovascular procedure was an option or who were not candidates for general anesthesia for any reason. Indications for surgery included disabling claudication in three patients (25%), ischemic rest pain in six patients (50%), and tissue loss or gangrene in three patients (25%). Three patients had a history of prior vascular surgery; one had a left iliofemoral bypass and two had bilateral common or external iliac endovascular reconstructions. All of the patients were active smokers (100%), ten had arterial hypertension (83%), eight had hyperlipemia (66%), and four had diabetes (33%). Five patients had a history of coronary disease (42%), and eight (67%) had previous chronic obstructive pulmonary disease (COPD) ( Table 1) . Preoperative daily treatment included aspirin 80 mg for five patients and clopidogrel for two patients. Those treatments were not interrupted prior to surgery. Aortic calcification, thrombus, plaque, and other morphologic variables were evaluated by CT scan, and no morphological variables affected the decision to perform EVREST. In order to apply an endovascular sutureless anastomosis, the patient had to have been diagnosed with TASC D aortoiliac occlusive lesions for which endovascular revascularization was not indicated.
Initial technical success, complications, preoperative and postoperative ankle brachial pressure index, assessment of bypass patency, and integrity of the proximal assembly were assessed, the latter by computed tomographic-angiography at 1 week, 1 month, 6 months, and 1 year.
Surgical technique
This technique has been described in a previous study. 12 To perform EVREST, each patient was positioned, under general anesthesia, in a 30 right lateral decubitus position. The operator, first assistant, and scrub nurse were on the left side of the patient. The videomonitor was positioned on the right side (Fig. 1) . A pneumo-peritoneum was created using a Veress needle introduced at the umbilicus. A 30 optical system was first inserted to check good positioning of three trocars in the left retroperitoneal space. After exsufflation of the pneumo-peritoneum, dissection of the retroperitoneal space was performed by CO 2 insufflation at a maximum pressure of 14 mmHg, and by blunt dissection with laparoscopic forceps. The left common iliac artery was easily visualized above the psoas muscle and dissected with monopolar electrocoagulation. The left ureter was then visualized and the aorta was isolated up to the left renal artery. One additional 12-mm trocar was placed between the 11th rib and the umbilicus, to support a laparoscopic aortic clamp (Aesculap, AG & Co KG Company). The aortic clamp was left open in the retroperitoneal space, being used as a retractor but ready to clamp the aorta in the event of uncontrolled bleeding. A 14/7 mm diameter bifurcated graft (Gelsoft Plus Bifurcate, Vascutek Terumo, UK) was inserted into the retroperitoneal space through the 12-mm trocar. Under videoscopic control, the prosthetic limbs were brought to the groins that had been previously dissected. The tunnel to the right groin was made by videoscopic vision and finger dissection along the iliac vessels. A laparoscopic grasping forceps was then introduced into the retroperitoneal space through the tunnel under videoscopic vision. The limbs were sealed by ligation prior to introduction of the bifurcated graft into the retroperitoneal space. An 18 gauge, 27 cm catheter needle (transhepatic cholangiography catheter needle, Cook Medical Inc., USA) was inserted through the left prosthetic limb into the retroperitoneal space. The left lateral side of the infrarenal aorta was then punctured at the level of the origin of the inferior mesenteric artery (Video 1). A 0.035 00 hydrophilic guide wire (Terumo Corporation, Tokyo, Japan) was positioned into the aorta. Heparin (100 IU/kg) was given intravenously. A pigtail catheter was positioned for angiography to localize the renal arteries. The hydrophilic guide was changed for a stiff guide wire (Lunderquist, Cook Medical Inc., USA). A 20 mm diameter and 80 mm length iliac extension of an Endurant stent-graft system (Medtronic, Endovascular, Santa Rosa, CA, USA) was introduced over the wire up to 4 cm into the aorta through the left prosthetic limb of the bifurcated graft (Fig. 2, Video 2) . The left limb was sealed with a protected grasping mosquito during the puncture of the aorta but no sealing was necessary while the stent graft was introduced into the left limb. The covered stent-graft, used as a connector, was deployed into the infra-renal aorta and into the main body of the bifurcated graft (Fig. 2) . The deployment was controlled by fluoroscopy and by direct retroperitoneal visualisation on the monitor. An 80 mm long, 20 mm diameter non-compliant balloon (Z-Med-X, Nu MED Canada inc., Cornwall, ON, Canada) was inflated at a controlled maximum pressure of 2.5 atmospheres to ensure sealing of the aorto-prosthetic junction and perfect deployment of the endograft (Fig. 2, Video 3 ). For the first two patients, a 10 mm diameter non-compliant balloon (Passeo-35, Biotronik, Berlin, Germany) and a compliant balloon (Coda balloon catheter, Cook Medical Inc., USA) were used, but there was concern that the small balloon might lead to restenosis in this cohort of heavy smokers so a switch was made to the 20 mm balloon for the last 10 patients. Restenosis was not observed at the 1-year computed tomographic angiography in the two patients who received the 10 mm balloon treatment (data not shown). The femoral anastomoses were performed by classic open surgery with 6/0 polypropylene running sutures (Fig. 3) . Prior to wound closure, videoscopic inspection was made of the abdominal cavity to assess bowel viability. Two drains were left in the retroperitoneal space for 24 hours, and one drain in each femoral access site.
Supplementary videos related to this article can be found online at http://dx.doi.org/10.1016/j.ejvs.2014.06.036.
The following are the Supplementary videos related to this article:Video 1The left lateral side of the aorta is punctured with a 27 cm catheter needle. Video 2Introduc-tion of the covered stent graft over the wire into the aorta. Video 3Final endoscopic vision.
Statistical analysis
Statistical analysis was done with Statistical Package for Social Sciences Software (SPSS Inc, Chicago, IL, USA). Preprocedural and post-procedural ABIs were compared by paired Student t test with Bonferroni correction. Statistical significance was set at p < .05.
RESULTS
All patients scheduled for EVREST underwent successful procedures. The retroperitoneal laparoscopic approach to the aorta was possible in every case. In each case, the bifurcated graft was connected to the covered stent-graft on the left side of the infrarenal aorta. Two connectors were used for the fourth patient because the extra-aortic overlap with the first connector was less than 2 cm. All procedures were conducted laparoscopically and no conversion to open surgery was needed. Operative time was defined as the time elapsed from the initial incision to the final skin closure. EVREST operative time was an average of 265 minutes (range 180e330 minutes). Deployment time was defined as the time needed for deployment of the stent-graft and for inflation of the balloon inside it. The median deployment time was 60 seconds (range 50e80 seconds) and during that time the use of the aortic clamp was necessary in four patients. The aorto-femoral time was defined as the time elapsed from the puncture of the aorta to the completion of both femoral anastomoses. Median aorto-femoral time was 53 minutes (range 25e85 minutes). No disruptions of the aorta or inferior mesenteric artery (IMA) were observed in the 12 cases. A bilateral femoral endarterectomy prior to the femoral anastomosis was necessary in two patients because of heavily calcified lesions. A stenosis of the left superficial femoral artery was concomitantly treated by endovascular surgery in one patient. Average blood loss was 680 mL (range 200e1400 mL). The average transfusion volume (cell-saver) was 360 mL (range 100e900 mL). Median intensive care unit stay was 32.4 hours (range 17e48 hours). All patients received intravenous analgesia followed by oral analgesics. No epidural catheter or patient-controlled analgesia pumps (PCA) were needed. Postoperative pain was clinically evaluated as moderate in nine patients and low in three patients. All patients had a nasogastric tube but it was removed at the end of the procedure in all cases. Median 24-hour diuresis was 1390 mL (range 900e2100 ml). No major postoperative complications or deaths were observed. None of the patients needed postoperative surgical revision. The median hospital stay was 6 days. Average hospital stay was 6.2 days (range 3e8 days) ( Table 1 ). All of the patients had a quick recovery with minimal wound pain. There was no postoperative bowel dysfunction. Postoperative medication consisted of oral aspirin (160 mg daily). The 30-day postoperative mortality rate was 0% (0/ 12). Patency was evaluated by clinical examination, ankle brachial index, and computed tomographic-angiography. All grafts were patent at a mean follow-up of 9.3 months (range 1e17 months), and there was no early or late disruption of the proximal assembly. The ankle brachial pressure index was improved in all cases. Primary patency rate was 100%. In one patient, the control angio-CT at 1 week showed a paraprosthetic retroperitoneal hematoma of 6 Â 10 cm, which did not require additional surgery. The size of the hematoma had decreased significantly at 3-month computed tomographic-angiography (Fig. 4) . Two patients underwent limited amputation of toes and one patient had an amputation of the calcaneum. One patient underwent a right femoropopliteal bypass 9 months after EVREST. One patient died at 6 months from acute respiratory failure, with a patent bypass.
DISCUSSION
Since 2004, the authors have performed several retroperitoneal aortobifemoral bypasses using a short left-sided transverse incision. This procedure, described by Charles Rob in 1963, 13 is not very popular because of the difficulties encountered in exposing the aorta. Using a surgical retractor system (Condor GmbH Medicaltechnik, Germany), the procedure remains challenging but feasible.
14 Increased experience has led to smaller incisions and this, coupled with the laparoscopic skills of the authors, made it feasible to attempt a retroperitoneal laparoscopic approach. Some patients successfully underwent total laparoscopic retroperitoneal aortobifemoral bypass. 9 The most popular method for laparoscopic aortobifemoral bypass is the pre-renal transperitoneal approach.
3À5, 15 However, regardless of the technique used, 3À5,8,9,15 the aortoprosthetic anastomosis is a major challenge that makes it unpopular despite obvious advantages for the patients. 15 In a study of laparoscopyassisted aneurysm resection, Kolvenbach et al. reported significant reductions in cytokine release supporting the notion that video-assisted surgery is less invasive and induces less tissue trauma compared with conventional surgery. 16 Vascular laparoscopic experts agree that the learning curve is long, that a mini-laparotomy is often needed to complete the aortic anastomosis, and that new materials are needed to make aortic suture more feasible. 4, 5, 17 Some vascular surgeons have presented new devices to facilitate aortic suture but those materials were generally used only in vitro, on pigs and cadavers, or only by the authors themselves. 17, 18 Connecting blood vessels today is done mostly the same way with sutures as it was 100 years ago, when the French surgeon Alexis Carrel described the technique in 1902. 19 This standard anastomotic technique requires a large exposure, circumferential dissection, and clamping of vessels. Moreover, classical surgical access can be quite difficult and time-consuming especially with patients who have heavily calcified vessels. 20 These concerns are all the more true for laparoscopic aortic surgery.
In 2007, Lachat 21 published the VORTEC technique (Viabahn Open Revascularisazion TEChnique), which is a clampless and sutureless method that appears to be faster, safer, and easier than classic arterial sutures for complex anastomoses in open surgery. Lachat described his experience of more than 300 cases in which he encountered no major bleeding or leaks. 22 This technique represents a significant improvement over traditional vascular anastomotic surgical techniques.
The present authors decided to apply this technique to total retroperitoneal laparoscopic aortobifemoral bypass. 12 Patients were selected based on their clinical stage (Fontaine classification) and on computed tomographic angiography. Inclusion criteria were Fontaine classification from stage II b (claudication <100 m) to IV (tissue loss), and aorto-iliac TASC D lesions with at least 4 cm of patent aorta beneath the renal arteries. Heavily calcified aorta and patency of inferior mesenteric artery were not exclusions for the technique (Table 2) . Exclusion criteria were juxtarenal thrombosis or thrombosed unilateral or bilateral external iliac artery with patent aorta and internal iliac arteries.
The aorta was clamped temporarily in four patients (33%) because of excessive bleeding when the connector was deployed. The clamp was removed when the non-compliant balloon was inflated into the connector. Median blood loss was less than that described for open surgery. 23 Operative mortality was 0% and there were no complications during surgery. It is important to keep in mind that conversion to open surgery with a short left-sided transverse incision is always possible if technical difficulties arise during the procedure.
There were no endoleaks at 9 months follow-up. The radial force of the endograft (which is not at its maximal diameter at the aortic wall passage) might explain the absence of endoleak during diastole. All of the patients treated with EVREST had heavily calcified aortas, forming a very-hard-to-break rigid aortic wall frame, which would be expected to prevent further tearing. However, a direct hammer effect on the aortostomy inferior edge leading to a leak could be an issue for patients with soft, non-calcified aorta.
The median operative time was close to those published in large laparoscopic series, 6, 7 but it must be considered that the last two patients had operative times close to the shorter range of those published series. With increased experience, the authors believe that the operative time for the procedure will decrease significantly.
Median hospital stay (6 days) and mean hospital stay (6.2 days, range 3e8 days) were shorter than those published in a study dealing with a comparable population who underwent open surgery (mean 12.8 days, range 6e81 days) or laparoscopic surgery (mean 7 days, range 3e19 days). 23 Lachat, who used an endograft connector in open surgery for aortoiliac occlusive disease with heavy calcified aorta, reported a mean hospital stay of 16.5 AE 12 days. 22 The prolonged discharge time was related to inexperience, social issues, and severe comorbidities associated with patients with TASC D lesions.
Conclusions
EVREST greatly facilitates laparoscopic aortic surgery in occlusive disease with no need for suturing or clamping of the aorta. The most attractive feature of EVREST is that it allows surgeons to avoid performing the technically challenging aortoprosthetic anastomosis. This technique, performed in a single center on 12 patients, seems to be feasible and safe. It offers the advantages of both laparoscopy and endovascular surgery, especially in the challenging conditions encountered during aortic laparoscopic surgery. This approach, using existing materials, could make laparoscopic aortic surgery for occlusive disease accessible to more vascular surgeons accustomed to laparoscopic surgery.
For patients who are candidates for an aortobifemoral bypass, the authors now propose EVREST as an alternative to an open procedure.
More patients are required to assess the value of this promising technique. As for other new techniques, the reproducibility and long-term outcomes of patients treated with EVREST will need to be evaluated, preferably in multicenter studies. However, this early experience supports procedural and initial postprocedural safety and demonstrates proof of concept for EVREST.
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